Evidence map›Paper›PMID 39679462›Full record

ArticleCombinatorial chemistry & high throughput screening2026

Sanggenol L Alleviates Rotenone-induced Parkinson's Disease, Inhibits Mitochondrial Complex I

Nan Zhao, Menghai Wu, Periyannan Velu, Vijayalakshmi Annamalai, Jianbin Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nan ZhaoInternal Medicine-Neurology, Harbin 242 Hospital, Harbin, 150066, China.
Menghai WuDepartment of Neurology, People's Hospital Affiliated to Shandong First Medical University, Shandong, 271199, China.
Periyannan VeluGalileovasan Offshore And Research And Development Pvt. Ltd, Nagapattinam, Tamil Nadu, 611002, India.
Vijayalakshmi AnnamalaiGalileovasan Offshore And Research And Development Pvt. Ltd, Nagapattinam, Tamil Nadu, 611002, India.
Jianbin ZhangDepartment of Neurosurgery, Shandong Provincial Third Hospital, Shandong University, Jinan, 250031, China.

Funding

Shandong Province Medicine and Health Science and Technology Plan Development Project 202304041276
6 · The paper itself

Abstract

backgroundParkinson's Disease (PD) is the age-associated, second most advanced neurodegenerative illness. Rotenone is an extensively used pesticide to study PD pathology and inhibits mitochondrial complex I. Reports indicate that rotenone exerts neurotoxicity by its capability to produce Reactive Oxygen Species (ROS), which eventually leads to neuronal apoptosis.

objectiveSanggenol L (SL) is an eminent flavonoid present in the Morus alba root bark, which exhibits neuroprotective, anticancer, and antioxidant properties. MATERIALS AND

methodsHence, we assessed the neuroprotective activity of SL (5 and 10 μM/ml) on rotenone-stimulated SK-NSH neuroblastoma cells and elucidated the effect of the P13K/AKT/mTOR signalling.

resultsThe anti-PD action of SL on proliferation, Oxidative Stress (OS), intracellular ROS, apoptosis, Bax, cleaved Caspase-12, -9, -3, and Cyt-c, Bcl-2 and P13K/AKT/mTOR signaling was determined by MTT assay, biochemical analysis, DCFDA, AO/EB staining and western blot. It was found that SL (5 and 10 μM/ml) reduced rotenone-triggered OS, ROS levels, and apoptosis in a concentration-related way. SL alleviates Bax, cleaved caspase-12, -9, -3, and Cytc, while reducing Bcl-2. Furthermore, SL safer mitochondria by increase MMP and suppresses phosphorylation of P13k/AKT/mTOR pathway, thereby regulating apoptotic signalling.

conclusionOur findings indicate that SL showed protective effects against rotenone-induced OS, mitochondrial complex-I in neuronal cell damage, which suggests that SL might potentially serve as an anti-PD remedial candidate for PD treatment.

Indexed as

Electron Transport Complex IFlavonesNeuroprotective AgentsParkinson DiseaseRotenoneApoptosisCell ProliferationCell SurvivalDose-Response Relationship, DrugHumansMitochondriaOxidative StressPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReactive Oxygen SpeciesSignal TransductionElectron Transport Complex IFlavonesMTOR protein, humanNeuroprotective AgentsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReactive Oxygen SpeciesRotenoneTOR Serine-Threonine Kinasesapoptosisoxidative stressP13K/AKT/mTOR.parkinson’s diseaserotenoneSanggenol L

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.